Press Release

Solvay Pharmaceuticals, Aerovectrx CEOs Named 2010 GaBio Board Leaders

Back to      Download PDF Version

ATLANTA, GA (January 6, 2010) –  Solvay Pharmaceuticals, Inc. President Stephen Hill has been named Chair of the Georgia Bio Board of Directors and Aerovectrx CEO Thomas Callaway has been named Vice Chair.

Stephen Hill, BM, BCh, MA, FRCS, and Thomas Callaway, M.D., MBA, assume leadership of GaBio in the midst of enormous challenges and opportunities for the life sciences industry. With dramatic health care reform looming, the election of a new Georgia governor, and an uncertain economic recovery, the industry is coping with changes that will force companies in new directions as they battle to develop innovative treatments and cures for the most intractable conditions, including cancer, cardiovascular diseases, diabetes, obesity, neurological disorders and infectious diseases.

GaBio likewise is embarking in new directions to assist its members in navigating the ever-more demanding regulatory and market environments. It also is mobilizing to take advantage of the excitement generated by the 2009 BIO International Convention, held for the first time in Atlanta. The convention solidified Georgia’s reputation as a global center of life sciences innovation. To build on this success, GaBio has adopted an aggressive mission and strategic plan to advance the growth of the life sciences industry and foster strategic partnerships that can create a healthier world.

GaBio’s members comprise an industry association with a record of achievement in three areas critical to the state’s future: improving the health of people, animals and the environment; expanding the number of high paying, advanced technology jobs; and enhancing K-12 student achievement in science education.

“Drs. Hill and Callaway provide GaBio’s Board of Directors with the leadership to launch initiatives that can help our members succeed in their endeavors and make our state a premier location for life sciences industry development,” said Charles Craig, GaBio President. For a complete list of the 2010 Board members visit www.gabio.org.

Dr. Stephen Hill
As president of Solvay Pharmaceuticals, Inc., Dr. Hill focuses on expanding the company’s presence in the U.S. through aggressive strategies to grow the current business together with pipeline development and acquisitions. He leads the executive committee, is a member of the corporation’s board of directors and an officer of the corporation. In addition, Dr. Hill serves as president of all Solvay Pharmaceuticals subsidiaries including Unimed Pharmaceuticals, Organics and Solvay Biologicals. 

Dr. Hill served as president and CEO of biotechnology firm ArQule from 1999-2008. Prior to his position at ArQule, Dr. Hill was Head of Global Drug Development at F. Hoffmann-La Roche from 1997-1999. He joined Roche in 1989 as Medical Adviser to Roche Products in the U.K. and held senior positions that included U.K. Medical Director and Head of international Drug Regulatory Affairs at Roche headquarters in Basel, Switzerland. Dr. Hill is a Fellow of the Royal College of Surgeons of England and holds his scientific and medical degrees from St. Catherine's College at Oxford University.

Dr. Thomas Callaway
After three years as an investor and board member, Dr. Callaway became the CEO of Aerovectrx in April and is leading the commercial enterprise. He is a founding partner of Georgia Venture Partners and involved in all aspects of GVP investment activities. He is also founder and president of Life Science Partner. A biotechnology executive, Dr. Callaway previously held the position of Director of Commercial Development for SyStemix and marketing roles at Roche Diagnostics and Roche Molecular Systems. He earned a medical degree from Vanderbilt University School of Medicine. He holds an MBA and undergraduate degree from Duke University.

About Georgia Bio
Georgia Bio, founded in 1989, is a private, nonprofit membership organization promoting the interests of the life sciences industry. GaBio members include nearly 300 pharmaceutical, biotech and medical device companies, research institutions and universities, medical centers, government groups and service providers involved in the research, development, manufacture and sales of products that improve health and well-being of people, animals and the environment.